Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Stock Short Interest Report for October

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totaling 2,971 shares, a growth of 193.6% from the September 30th total of 1,012 shares. Based on an average trading volume of 31,943 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Cardio Diagnostics currently has an average rating of “Sell”.

Cardio Diagnostics Trading Down 4.6%

NASDAQ CDIO traded down $0.08 on Friday, hitting $1.67. 12,036 shares of the company were exchanged, compared to its average volume of 1,226,639. The stock has a fifty day moving average of $1.88 and a 200-day moving average of $2.07. The company has a market cap of $4.94 million, a PE ratio of -0.57 and a beta of 2.29. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $7.91.

Cardio Diagnostics (NASDAQ:CDIO) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.51) EPS for the quarter. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 82.28%. The firm had revenue of $0.01 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC purchased a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned 0.52% of Cardio Diagnostics as of its most recent SEC filing. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care.

The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.